RECURRENT GRADE 1 FOLLICULAR LYMPHOMA

This early-phase trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have returned or not improved after standard treatments. The drug is a monoclonal antibody designed to help the immune system fight cancer. The main goals are to find the …

This study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs work together. About 36 adults with specific …

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests whether combining two immunotherapy drugs (rituximab and pembrolizumab) with or without a chemotherapy drug (lenalidomide) can shrink tumors in people whose follicular lymphoma or diffuse large B-cell lymphoma has returned after prior treatment. About 53 adults w…

This early-phase study tests a new type of immunotherapy for people with high-risk B-cell non-Hodgkin lymphoma that has come back after initial treatment. Participants first receive a stem cell transplant, then get an infusion of their own immune cells that have been genetically …

This early-stage study tested a combination of two drugs—pembrolizumab (an immunotherapy) and vorinostat (a targeted therapy)—in 52 adults with certain types of lymphoma that had returned or stopped responding to standard treatments. The main goals were to find the safest dose of…

This study tests a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. The drug works by blocking certain enzymes that help cancer cells grow. The main goal is to see how many patients have their tumors shrink or disappe…

This study tests a combination of two drugs, epcoritamab and tazemetostat, in people with a type of blood cancer called follicular lymphoma that has come back or not responded to prior treatments. The goal is to see if the combination is safe and effective at shrinking or elimina…

This early-phase trial tests the safety and best dose of specially modified T-cells (immune cells) given after a stem cell transplant for people with high-risk or returning non-Hodgkin lymphoma. The modified T-cells are designed to recognize and attack cancer cells. The study inv…

This early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …